Anticancer Drug Development, System Updating and Global Participations

Background: New anticancer drug discovery, development and manufacture entered the bottleneck stage. Many limitations of both technology and animal models slow down the anticancer drug developments Objective: To ease economic burdens for drug developers and general patient populations. Methods: Key factors affecting anticancer drug developments and possible roadmaps for updating drug screening routines worldwide are suggested. Results: Drug development chains must be updated and better drug development paradigms must be established. Conclusions: This world welcomes global participations in anticancer drug developments and utilities.